Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9B2W

PIV3 HN with Fab 13

9B2W の概要
エントリーDOI10.2210/pdb9b2w/pdb
分子名称Hemagglutinin-neuraminidase, Fab 13 Heavy Chain, Fab 13 Light Chain, ... (10 entities in total)
機能のキーワードhn, hemagglutinin neuraminidase, complex, antibody complex, viral protein, viral protein-immune system complex, viral protein/immune system
由来する生物種Human respirovirus 3
詳細
タンパク質・核酸の鎖数6
化学式量合計201494.45
構造登録者
Durie, I.A.,Mousa, J.J. (登録日: 2024-03-17, 公開日: 2024-12-04, 最終更新日: 2025-01-15)
主引用文献Miller, R.J.,Durie, I.A.,Gingerich, A.D.,Elbehairy, M.A.,Branch, A.G.,Davis, R.G.,Abbadi, N.,Brindley, M.A.,Mousa, J.J.
The structural basis of protective and nonprotective human monoclonal antibodies targeting the parainfluenza virus type 3 hemagglutinin-neuraminidase.
Nat Commun, 15:10825-10825, 2024
Cited by
PubMed Abstract: Parainfluenza virus 3 (PIV3) infection poses a substantial risk to vulnerable groups including infants, the elderly, and immunocompromised individuals, and lacks effective treatments or vaccines. This study focuses on targeting the hemagglutinin-neuraminidase (HN) protein, a structural glycoprotein of PIV3 critical for viral infection and egress. With the objective of targeting these activities of HN, we identified eight neutralizing human monoclonal antibodies (mAbs) with potent effects on viral neutralization, cell-cell fusion inhibition, and complement deposition. Three epitopes on PIV3 HN were delineated and one epitope, Site 2, elicits a mAb with cross-neutralizing ability against PIV1 and PIV3. Cryo-EM revealed the cross-neutralizing mAb utilizes a long CDR3 loop to bind inside the pocket of the sialic acid binding site. Additionally, we resolved the structure of a non-protective mAb binding to Site 1 near the HN:F-interaction site. The potent Site 2-directed mAb demonstrated clinical efficacy in hamsters, reducing viral replication prophylactically and therapeutically. These findings advance our understanding of PIV3 immunity and underscore the significance of targeting HN for clinical therapeutic development against PIV3.
PubMed: 39738006
DOI: 10.1038/s41467-024-55101-4
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.51 Å)
構造検証レポート
Validation report summary of 9b2w
検証レポート(詳細版)ダウンロードをダウンロード

248335

件を2026-01-28に公開中

PDB statisticsPDBj update infoContact PDBjnumon